3518-76-1

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenethylpiperidin-4-ol is used as a key intermediate in the synthesis of 1-Pyrrolidinyl Indane derivatives, which are Histamine H3 receptor antagonists. These antagonists are useful in the treatment of various diseases by modulating the histamine signaling pathway, which plays a crucial role in immune response, neurotransmission, and other physiological processes.
In the development of new drugs, 1-Phenethylpiperidin-4-ol serves as a versatile building block due to its unique chemical structure and biological activities. Its application in the pharmaceutical industry is primarily focused on the creation of novel therapeutic agents that target specific receptors or pathways involved in disease progression.

InChI:InChI=1/C13H19NO/c15-13-7-10-14(11-8-13)9-6-12-4-2-1-3-5-12/h1-5,13,15H,6-11H2

Upstream product

• 50-00-0 formaldehyd 
• 18191-59-8 allylsilane 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 103-63-9 1-phenyl-2-bromoethane 
• 122-78-1 phenylacetaldehyde 

Downstream Products

• 39742-60-4 1-(2-phenylethyl)-4-piperidinone 
• 875229-49-5 C₂₆H₂₉NO 
• 3685-71-0 diphenyl-acetic acid-(1-phenethyl-[4]piperidyl ester) 
• 85387-30-0 acetoacetic acid-N-phenethyl-4-piperidinyl ester 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel copper-chelating acetylcholinesterase inhibitors with pyridine N-benzylpiperidine fragments

Cholinergic depletion is the direct cause of disability and dementia among AD patients. AChE is a classical and key target of cholinergic disorders. Some new inhibitors of AChE combining pyridine, acylhydrazone and N-benzylpiperidine fragments were developed in this work. The hit structure was optimized to yield the compound 21 with an IC50 value of 6.62 nM against AChE, while almost no inhibitory effect against BChE. ADMET predictions and PAMPA permeability evaluation showed good drug-like property. The higher activity with an intermediate alkyl chain substitution indicates a new binding mode of inhibitor with AChE. This finding provides new insights into the binding mechanism and is helpful for discovery of novel high-activity AChE inhibitors.

Design and synthesis of new bifunctional sigma-1 selective ligands with antioxidant activity

Herein we report the synthesis of new bifunctional sigma-1 (σ1)-selective ligands with antioxidant activity. To achieve this goal, we combined the structure of lipoic acid, a universal antioxidant, with an appropriate sigma aminic moiety. Ligands 14 and 26 displayed high affinity and selectivity for σ1 receptors (K iσ1 = 1.8 and 5.5 nM; Kiσ 2/σ1 = 354 and 414, respectively). Compound 26 exhibited in vivo antiopioid effects on kappa opioid (KOP) receptor-mediated analgesia. In rat liver and brain mitochondria (RLM, RBM), this compound significantly reduced the swelling and the oxidation of thiol groups induced by calcium ions. Our results demonstrate that the tested compound has protective effects against oxidative stress.

Antimycobacterial activity of diphenylpyraline derivatives

2-Substituted derivatives of diphenylpyraline and their 1-phenyl and 1-phenethyl analogues have been prepared in several steps from dihydropyridine-2(1H)-thiones. The structures of all new compounds have been confirmed by NMR spectroscopy. Their activity against Mycobacterium tuberculosis H37Rv as well as their cytotoxicity against human cells (HEK-293) have been determined via in vitro assays. The antimycobacterial potency was in general increased by substitution in ring position 2. The most promising modifications were a 2-isopropyl derivative and a 1,2-diphenyl analogue.

Concise and versatile syntheses of N-arylalkylpiperidines as potential intermediates for 4-anilidopiperidine analgesics

N-Arylalkylpiperidones and N-arylalkylspiroepoxypiperidine as potential intermediates for 4-anilidopiperidine analgesics and their structural analogues have been efficiently synthesized from the simple arylalkylamines by two and three step sequences respectively.